Comfort · adults in the ICU, requiring respiratory support
2 findings from 1 review
Comfort · adults in the ICU, requiring respiratory support
2 findings from 1 review
Intervention not reported
Withdrawals Participant withdrawal following randomization before or during receipt of the intervention because of consent or medical reason · adult survivors of critical illness
1 finding from 1 review
Lowest recorded SpO2 (%) · people requiring tracheal intubation
1 finding from 1 review
Intervention not reported
Grief in the relatives ICG (0 to 95; > 25 = presence of complicated grief) measured at 12 months TRIG (21 to 105; lower scores indicate higher levels of grief) measured at 3 and 9 months · relatives, patients, and healthcare professionals during resucitation
1 finding from 1 review
Cognitive functioning b) Executve functioning (DEX score) (scores range from 0 to 80. Lower scores indicate better functioning) (DEX) · critically ill patients 18 years or older treated for respiratory failure or septic or both, cardiogenic or haemorrhagic shock who resided…
1 finding from 1 review
Incidence of acute mountain sickness (AMS)‐ Follow‐ up: From arrival to 24 hours later · participants at risk of high altitude illness
Acetazolamide probably leads to lower incidence of acute mountain sickness (AMS)‐ Follow‐ up: From arrival… compared with placebo (moderate certainty).
1 finding from 1 review
Incidence of acute mountain sickness (AMS)‐ Follow‐ up: From arrival to 24 hours later · participants at risk of high altitude illness
Dexamethasone showed no clear difference in incidence of acute mountain sickness (AMS)‐ Follow‐ up: From arrival… compared with placebo (low certainty).
1 finding from 1 review
Adverse events: General‐ Follow‐ up: From arrival to 24 hours later · participants at risk of high altitude illness
1 finding from 1 review
Risk of high altitude pulmonary oedema · participants at risk of high altitude illness
1 finding from 1 review
Incidence of high altitude cerebral oedema (HACE) ‐ not reported · participants at risk of high altitude illness
Acetazolamide showed no clear difference in incidence of high altitude cerebral oedema (HACE)‐ Follow‐ up: From… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events: Paresthesias‐ Follow‐ up: From arrival to 24 hours later · participants at risk of high altitude illness
Acetazolamide may leads to higher adverse events: Paresthesias‐ Follow‐ up: From arrival to 24 hours… compared with placebo (low certainty).
1 finding from 1 review
Side effects or other adverse events · participants at risk of high altitude illness
Acetazolamide may leads to higher adverse events: side effects‐ Follow‐ up: From arrival to 24 hours… compared with placebo (low certainty).
1 finding from 1 review
Incidence of acute mountain sickness (AMS)‐ Follow‐ up: From arrival to 24 hours later · participants at risk of high altitude illness
Budesonide may leads to lower incidence of acute mountain sickness (AMS)‐ Follow‐ up: From arrival… compared with placebo (low certainty).
1 finding from 1 review
Side effects or other adverse events · participants at risk of high altitude illness
1 finding from 1 review
Low oxygen delivery (DO2)h ‐ not reported · critically ill adult patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Subgroup analysis of longer‐term mortality: lower tidal volume ventilationAlive or dead · adults with acute respiratory failure
Mortality: prone position probably leads to lower subgroup analysis of longer‐term mortality: lower tidal volume… compared with supine (moderate certainty).
1 finding from 1 review
All‐cause mortality ‐ sensitivity analysis · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies showed no clear difference in anti‐endotoxin, all‐cause mortality ‐ low risk of bias studies compared with placebo (moderate certainty).
1 finding from 1 review
Anti‐cytokine, all‐cause mortality ‐ low risk of bias studies · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies leads to lower anti‐cytokine, all‐cause mortality ‐ low risk of bias studies compared with placebo (high certainty).
1 finding from 1 review
All‐cause mortality, neonates, standard polyclonal IVIG · neonates with sepsis, severe sepsis and septic shock
Polyclonal intravenous immunoglobulin (IVIG) showed no clear difference in low risk of bias neonate studies, mortality all‐cause ‐ standard IVIG compared with placebo or no intervention (high certainty).
1 finding from 1 review